Progress in the management of advanced renal cell carcinoma (RCC)
- PMID: 20094957
- DOI: 10.1055/s-0030-1247237
Progress in the management of advanced renal cell carcinoma (RCC)
Abstract
A more profound understanding in the pathophysiological mechanism of renal cell cancer has led to a shift in the treatment approach. Traditionally, cytokines were the frontline drugs, but recently this has transitioned to drugs interacting vascular endothelial growth factor (VEGF) related pathway. Sorafenib, sunitinib, bevacizumab, temsirolimus and everolimus have demonstrated clinical improvements in randomized trials. The purpose of this review is to summarise the current management of advanced RCC.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
